These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 35739379)
1. Protein Tyrosine Phosphatase SHP2 Controls Interleukin-8 Expression in Breast Cancer Cells. Amante RJ; Auf der Maur P; Richina V; Sethi A; Iesmantavicius V; Bonenfant D; Aceto N; Bentires-Alj M J Mammary Gland Biol Neoplasia; 2022 Jun; 27(2):145-153. PubMed ID: 35739379 [TBL] [Abstract][Full Text] [Related]
2. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop. Aceto N; Sausgruber N; Brinkhaus H; Gaidatzis D; Martiny-Baron G; Mazzarol G; Confalonieri S; Quarto M; Hu G; Balwierz PJ; Pachkov M; Elledge SJ; van Nimwegen E; Stadler MB; Bentires-Alj M Nat Med; 2012 Mar; 18(4):529-37. PubMed ID: 22388088 [TBL] [Abstract][Full Text] [Related]
3. PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer. Amante RJ; Jehanno C; De Silva D; Coissieux MM; Ackerknecht M; Romanet V; Sethi A; Hamelin B; Preca BT; Piscuoglio S; Ng CKY; Mohseni M; Bentires-Alj M J Mammary Gland Biol Neoplasia; 2023 Jun; 28(1):13. PubMed ID: 37294349 [TBL] [Abstract][Full Text] [Related]
4. Src homology-2 domain-containing protein tyrosine phosphatase (SHP) 2 and p38 regulate the expression of chemokine CXCL8 in human astrocytes. Mamik MK; Ghorpade A PLoS One; 2012; 7(9):e45596. PubMed ID: 23029125 [TBL] [Abstract][Full Text] [Related]
5. Shp2 Plays a Critical Role in IL-6-Induced EMT in Breast Cancer Cells. Sun X; Zhang J; Wang Z; Ji W; Tian R; Zhang F; Niu R Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208810 [TBL] [Abstract][Full Text] [Related]
6. Src-homology 2 domain-containing tyrosine phosphatase 2 promotes oral cancer invasion and metastasis. Wang HC; Chiang WF; Huang HH; Shen YY; Chiang HC BMC Cancer; 2014 Jun; 14():442. PubMed ID: 24931737 [TBL] [Abstract][Full Text] [Related]
7. The tyrosine phosphatase SHP2 increases robustness and information transfer within IL-6-induced JAK/STAT signalling. Fiebelkow J; Guendel A; Guendel B; Mehwald N; Jetka T; Komorowski M; Waldherr S; Schaper F; Dittrich A Cell Commun Signal; 2021 Sep; 19(1):94. PubMed ID: 34530865 [TBL] [Abstract][Full Text] [Related]
8. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase. Ruess DA; Heynen GJ; Ciecielski KJ; Ai J; Berninger A; Kabacaoglu D; Görgülü K; Dantes Z; Wörmann SM; Diakopoulos KN; Karpathaki AF; Kowalska M; Kaya-Aksoy E; Song L; van der Laan EAZ; López-Alberca MP; Nazaré M; Reichert M; Saur D; Erkan MM; Hopt UT; Sainz B; Birchmeier W; Schmid RM; Lesina M; Algül H Nat Med; 2018 Jul; 24(7):954-960. PubMed ID: 29808009 [TBL] [Abstract][Full Text] [Related]
9. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer. Matalkah F; Martin E; Zhao H; Agazie YM Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598 [TBL] [Abstract][Full Text] [Related]
10. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227 [TBL] [Abstract][Full Text] [Related]
11. Tyrosine phosphatase Shp2 mediates the estrogen biological action in breast cancer via interaction with the estrogen extranuclear receptor. Li J; Kang Y; Wei L; Liu W; Tian Y; Chen B; Lin X; Li Y; Feng GS; Lu Z PLoS One; 2014; 9(7):e102847. PubMed ID: 25048202 [TBL] [Abstract][Full Text] [Related]
12. SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer. Chen H; Libring S; Ruddraraju KV; Miao J; Solorio L; Zhang ZY; Wendt MK Oncogene; 2020 Dec; 39(49):7166-7180. PubMed ID: 33033382 [TBL] [Abstract][Full Text] [Related]
13. PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer. Chen X; Zou F; Hu Z; Du G; Yu P; Wang W; Wang H; Ye L; Tian J Toxicol Appl Pharmacol; 2020 Jul; 398():115019. PubMed ID: 32335126 [TBL] [Abstract][Full Text] [Related]
14. Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Fernandis AZ; Prasad A; Band H; Klösel R; Ganju RK Oncogene; 2004 Jan; 23(1):157-67. PubMed ID: 14712221 [TBL] [Abstract][Full Text] [Related]
15. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Badache A; Hynes NE Cancer Res; 2001 Jan; 61(1):383-91. PubMed ID: 11196191 [TBL] [Abstract][Full Text] [Related]
16. Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression. Schaper F; Gendo C; Eck M; Schmitz J; Grimm C; Anhuf D; Kerr IM; Heinrich PC Biochem J; 1998 Nov; 335 ( Pt 3)(Pt 3):557-65. PubMed ID: 9794795 [TBL] [Abstract][Full Text] [Related]
17. SHP2 promotes proliferation of breast cancer cells through regulating Cyclin D1 stability Yuan Y; Fan Y; Gao Z; Sun X; Zhang H; Wang Z; Cui Y; Song W; Wang Z; Zhang F; Niu R Cancer Biol Med; 2020 Aug; 17(3):707-725. PubMed ID: 32944401 [No Abstract] [Full Text] [Related]
18. A tyrosine phosphatase SHP2 gain-of-function mutation enhances malignancy of breast carcinoma. Hu Z; Wang X; Fang H; Liu Y; Chen D; Zhang Q; Liu X; Wei D; Qu C; Wang S Oncotarget; 2016 Feb; 7(5):5664-76. PubMed ID: 26673822 [TBL] [Abstract][Full Text] [Related]
19. Valencia-Sama I; Ladumor Y; Kee L; Adderley T; Christopher G; Robinson CM; Kano Y; Ohh M; Irwin MS Cancer Res; 2020 Aug; 80(16):3413-3423. PubMed ID: 32586982 [TBL] [Abstract][Full Text] [Related]
20. [SHP2 and MKP5 in P2Y purinergic receptor-mediated prostate cancer invasion]. He HY; Zheng J; Li Y; Heng WJ; Fang WG Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):288-92. PubMed ID: 16181551 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]